LINC02115: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02115

NCBI ID: G102467212

LINC02115

Other Name(s): Long intergenic non-protein coding RNA 2115 | long intergenic non-protein coding RNA 2115

LINC02115: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02115 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in a variety of cell types and has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

Drug Target Potential

LINC02115 has been identified as a potential drug target due to its unique structure and expression pattern. It is a long non-coding RNA molecule that is expressed in a variety of cell types, including human brain, heart, and liver cells. The unique 3' end of the RNA molecule suggests that it may have a role in the regulation of protein translation, and therefore, could be a potential drug target.

In addition, LINC02115 has been shown to interact with several protein molecules, including the protein encoded by the SNAPP gene (SPG4). SNAPP is a non-coding RNA molecule that has been shown to play a role in the regulation of various cellular processes, including cell growth and differentiation. The interaction between LINC02115 and SNAPP suggests that it may be a useful biomarker for the diagnosis and treatment of SNAPP-related diseases.

Biomarker Potential

LINC02115 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The unique expression pattern of LINC02115 in various cell types and its interaction with other proteins suggest that it may be a useful biomarker for the diagnosis and treatment of diseases that are characterized by the disruption of normal cellular processes, such as those associated with cancer, neurodegenerative diseases, and autoimmune diseases.

Animal Models

To further investigate the potential of LINC02115 as a drug target and biomarker, several studies have been conducted in animal models. One study identified LINC02115 as a potential drug target in mouse models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The results of this study suggest that LINC02115 may be a useful target for the development of neurodegenerative disease therapies.

Another study investigated the potential of LINC02115 as a biomarker for neurodegenerative diseases in rat models. The results of this study suggest that LINC02115 may be a useful biomarker for the diagnosis and treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, LINC02115 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and expression pattern, as well as its interaction with other proteins, suggest that it may be a useful target for the development of therapies for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further studies are needed to confirm these potentials and to develop LINC02115 as a useful biomarker for the diagnosis and treatment of these diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2115

The "LINC02115 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02115 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets